Can cancer-style T-cell engagers reset autoimmune disease without manufacturing CAR-T cells?
Bispecific T-cell engagers developed for blood cancers are being repurposed to eliminate pathogenic B cells and plasma cells in severe autoimmune disease, potentially offering CAR-T-like depth without individualized cell manufacturing.